Improving socio-economic outcomes for persons with dementia and informal caregivers
Issued by European Commission · via EU Funding & Tenders Portal
- Published
- 18 Nov 2026
- Closes
- 4 May 2027
- Reference
- HORIZON-CL2-2027-02-TRANSFO-09-two-stage
- Location
- European Union
- Sector
- Healthcare & Pharma
At a glance
European Commission in European Union has published a funding call in healthcare & pharma: “Improving socio-economic outcomes for persons with dementia and informal caregivers”. Submissions close on 4 May 2027, 167 days from today. Quote reference HORIZON-CL2-2027-02-TRANSFO-09-two-stage in any correspondence with the buyer. FreeTender has recorded 428 notices from this buyer since 2026, 406 of them currently open. There are 34 open healthcare & pharma notices in European Union on FreeTender. Bids are submitted to the buyer through EU Funding & Tenders Portal, not through FreeTender.
Key requirements
Taken from the notice by FreeTender. The tender document on the official portal is binding — check it, and any corrigendum, before you bid.
To bid on EU public procurement
Most EU buyers ask for the European Single Procurement Document (ESPD) as a self-declaration with the bid. Submission is on the e-procurement platform named in the notice.
Details
Expected Outcome:
Projects should contribute to all of the following expected outcomes:
- Persons with dementia experience improved social, mental and socio-economic outcomes through the development and implementation of person-centred interventions that enhance autonomy, inclusion, and quality of life.
- Informal caregivers benefit from reduced emotional, financial, and physical burden thanks to evidence-based support measures, policies, and services that improve their well-being and economic resilience.
- Support networks, long-term care and healthcare systems provide more integrated and accessible care for people with dementia and their caregivers through strengthened coordination between healthcare providers, long-term care and social services, and community organisations.
- Researchers (including from SSH disciplines) and policymakers have access to improved, gender-sensitive data on dementia care to inform policies (in particular national strategies and EU aging policy), optimise resource allocation, and enhance the effectiveness of care models.
Scope:
Dementia is a progressive neurological disease. The number of people with dementia will double by 2050 in the European Union, from 10 million currently. As people with dementia lose their ability to care for themselves, care is often provided by informal caregivers, which mostly include family members, and more specifically women. In fact, 71% of the estimated time devoted to unpaid care for people with dementia is devoted by women. Women, especially those in vulnerable situations such as those from lower socio-economic backgrounds, often face additional pressures in managing caregiving responsibilities, which may exacerbate pre-existing inequalities. Furthermore, the provision of informal care has a negative impact on the economic and social life of the caregiver, as the time spent on the person with dementia is time not spent in employment or with other friends and family. Additionally, informal care is unpaid and has been estimated to have negative financial consequences for the caregivers themselves and the society as a whole. Studies have also shown that people with dementia and their informal caregivers have higher rates of depression than the general population. While there is a lot of attention for clinical research, there is far less attention for the aspects surrounding the economic and social life, financial stability and the mental health of persons with dementia and informal caregivers. Many innovative solutions have been proposed, but few have been implemented on a wide scale. Social public policies with different design and funding that take into account the substitution and complementarities between formal and informal caregivers have been implemented to reduce the burden of the informal caregivers. What is needed, are systemic interventions focussed on improving these aspects for patients and informal caregivers and addressing the gendered nature of caregiving. Priority should be given to scaling up and contextualising interventions that have already shown promise or effectiveness at smaller scale, rather than developing entirely new or untested solutions. Applicants should provide a robust methodological framework for evaluating the effectiveness of the interventions. Proposals should also assess the economic feasibility and sustainability of the interventions, including cost-effectiveness and potential integration into existing health and social care systems or policy frameworks. Proposals can focus on groups in vulnerable situations (e.g. migrants, lower socio-economic populations, people with disabilities) for gender-responsive and inclusive interventions. Social inequality analyses are therefore also recommended. Community based models (e.g. dementia-friendly cities, peer-support groups) can be included, as well as analyses of the quality of residence of people with dementia. Proposals are encouraged to include technology and digital tools in the scope of their work. Considering the already high burden of dementia, interventions should be implemented in at least four Member States or Associated Countries. Considering the focus, it is of the upmost importance that informal caregivers are involved in the research throughout (in the design and implementation) to ensure that interventions are tailored to the real needs of caregivers and the individuals they care for. Proposals should outline clear, evidence-based strategies for tailoring, deploying, and assessing these interventions at individual, family, community, and societal levels, while addressing the specific needs of different caregiver demographics.
Submissions open on 02 March 2027.
Part of call HORIZON-CL2-2027-02-TWO-STAGE
Type of action: HORIZON Research and Innovation Actions
Programme period: 2021 - 2027
Priorities: AI, DigitalAgenda, SocInnov, SocietalEngagement, SSH
"> General conditions
1. Admissibility Conditions: Proposal page limit and layout
Applicants submitting a proposal for a blind evaluation (see General Annex F) must not disclose their organisation names, acronyms, logos nor names of personnel in the proposal abstract and Part B of their first-stage application (see General Annex E).
As described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
As described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide .
3. Other Eligible Conditions
As described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
As described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
The first-stage proposals of this topic will be evaluated blindly.
In addition, as described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
As described in Annex F of the Work Programme General Annexes and the Online Manual .
5c. Evaluation and award: I
Context for bidders
We hold 428 notices from European Commission, going back to August 2026 — 406 of them still open. They buy mostly in IT & Telecom, Water & Environment and Forestry & Wildlife. There are 34 open Healthcare & Pharma tenders in European Union. This one closes in 167 days.
More from this buyer
- Strengthening plant health: addressing emerging plant pest risks· closes 8 Apr
- Impact of malicious use of Open-Source Intelligence on critical infrastructure business continuity· closes 4 Nov
- Advancing bio-printing of living cells for regenerative medicine· closes 16 Sept
- Higher Voltage, Megawatt Charging System compatible, modular powertrain for Heavy Duty Vehicles (HDV) (2ZERO Partnership)· closes 14 Apr
- Large scale operational validation and upscaling of state-of-the-art (Generative) AI tools and models powering a next generation digital energy system· closes 31 Mar
Similar Healthcare & Pharma tenders
- Towards the next generation of frontier Artificial Intelligence models for healthcare· closes 16 Sept
- Transforming the Health and Care Workforce for Sustainable and Resilient Systems· closes 21 Jan
- Towards a consolidated culture and creativity driven European innovation ecosystem· closes 23 Sept
- Advancing bio-printing of living cells for regenerative medicine· closes 16 Sept
- Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers· closes 16 Sept
Explore European Union
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Тест-системы для лабораторной диагностикиГОСУДАРСТВЕННОЕ УЧРЕЖДЕНИЕ ЗДРАВООХРАНЕНИЯ "ГРЯЗИНСКАЯ ЦЕНТРАЛЬНАЯ РАЙОННАЯ БОЛЬНИЦА" · Russia
- Поставка расходных материалов для нужд клинико-диагностической лабораторииГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ ЗДРАВООХРАНЕНИЯ "ТУАПСИНСКАЯ РАЙОННАЯ БОЛЬНИЦА № 3" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ КРАСНОДАРСКОГО КРАЯ · Russia
- Поставка лекарственного препарата для медицинского применения МНН ДАУНОРУБИЦИН из перечня ЖНВЛПМИНИСТЕРСТВО ИМУЩЕСТВЕННЫХ И ЗЕМЕЛЬНЫХ ОТНОШЕНИЙ ВЛАДИМИРСКОЙ ОБЛАСТИ · Russia
- Поставка лекарственных препаратовДЕПАРТАМЕНТ КОНТРАКТНОЙ СИСТЕМЫ КУЗБАССА · Russia
- Аминосалициловая кислотаДЕПАРТАМЕНТ ГОСУДАРСТВЕННЫХ ЗАКУПОК СВЕРДЛОВСКОЙ ОБЛАСТИ · Russia
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →